P592 Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experience

Abstract

Background: Vedolizumab is an alpha4beta7 integrin antagonist which blocks gut-specific leucocyte migration. It is indicated for induction and maintenance of remission in moderate to severe ulcerative colitis (UC) and Crohn's disease.1 The aim of this study was to characterise the use and efficacy of vedolizumab in the induction and maintenance of remission in UC patients at University College London Hospital, a tertiary UK IBD centre. Method(s): A retrospective review of all UC patients initiated on vedolizumab from October 2015 to November 2016 was completed. A 52-week follow-up was completed on all patients. Patient characteristics and clinical review data with SCCAI score were collected. Clinical response was defined as a reduction of SCCAI to <3 from baseline at Week 14, 30 and Week 52. Clinical remission was defined as SCCAI